Private Asset Management increased its stake in Juno Therapeutics Inc (NASDAQ:JUNO) by 23.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The hedge fund owned 6,375 shares of the biopharmaceutical company’s stock after buying an additional 1,225 shares during the period. Private Asset Management’s holdings in Juno Therapeutics were worth $280,000 as of its most recent SEC filing.

Juno Therapeutics Inc (NASDAQ:JUNO) traded down 4.03% during trading on Tuesday, hitting $31.19. The stock had a trading volume of 1,187,635 shares. The firm’s market capitalization is $3.14 billion. Juno Therapeutics Inc has a 1-year low of $30.00 and a 1-year high of $69.28. The firm has a 50 day moving average price of $41.12 and a 200-day moving average price of $45.28.

Juno Therapeutics (NASDAQ:JUNO) last issued its earnings results on Tuesday, November 10th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by $0.12. The firm earned $1.60 million during the quarter, compared to the consensus estimate of $6.41 million. On average, equities research analysts expect that Juno Therapeutics Inc will post ($1.65) EPS for the current year.

JUNO has been the topic of several analyst reports. Leerink Swann upped their target price on Juno Therapeutics from $56.00 to $65.00 in a report on Wednesday, November 11th. FBR & Co. reiterated a “buy” rating and set a $73.00 target price on shares of Juno Therapeutics in a report on Monday, January 11th. Vetr lowered Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $53.18 target price on the stock. in a report on Wednesday, October 7th. Standpoint Research upgraded Juno Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, December 15th. Finally, Goldman Sachs began coverage on Juno Therapeutics in a report on Wednesday, November 18th. They set a “neutral” rating and a $50.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Juno Therapeutics has an average rating of “Buy” and an average price target of $60.32.

In other news, Director Richard Klausner sold 12,000 shares of the firm’s stock in a transaction dated Friday, November 13th. The stock was sold at an average price of $49.51, for a total value of $594,120.00. Following the completion of the sale, the director now directly owns 930,499 shares in the company, valued at approximately $46,069,005.49. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, General Counsel Bernard J. Cassidy sold 3,200 shares of the firm’s stock in a transaction dated Thursday, November 19th. The shares were sold at an average price of $52.97, for a total value of $169,504.00. Following the completion of the sale, the general counsel now owns 71,200 shares of the company’s stock, valued at $3,771,464. The disclosure for this sale can be found here.

Juno Therapeutics, Inc. (NASDAQ:JUNO) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Juno’s other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.

12 Month Chart for NASDAQ:JUNO

Receive News & Ratings for Juno Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.